IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Tempest Therapeutics Inc (OVASUSD)

CUSIP: 87978U108 | X1 | 76 institutional holders

Quarters

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/AVersant Vantage II, L.P.
with Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Ventures VI Gp-Gp, LLC, +3 more
162,9721.1%Newly reportedMar 30, 2026No 13F filer matched
13D/AVersant Vantage II, L.P.162,972
1.1% of class · Mar 30, 2026Newly reported
with Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Ventures VI Gp-Gp, LLC, +3 more
No 13F filer matched

Institutional Holders — Q2 2026

Versant Venture Management, LLC269,772
0.2% of portfolio›$299.4K
StyleTurnoverLocationFiled
Versant Venture Management, LLC
269,772$299.4K0.2%Deep ValueMediumSan Francisco, CA2026-08-12